JPWO2020240472A5

JPWO2020240472A5 -

Info

Publication number: JPWO2020240472A5
Application number: JP2021571513A
Authority: JP
Publication date: 2023-06-14

Claims

about 2% to about 80% by weight of lysozyme;
from about 2% to about 40% by weight of a pharmaceutically acceptable chelating agent;
from about 0.7% to about 20% by weight of a pharmaceutically acceptable pH-stabilizing salt having a buffering capacity in the range of pH 3.0 to pH 7.0; said weight percentage being the total weight of the pharmaceutical formulation; A pharmaceutical formulation for administration to a mammal, which is

2. The pharmaceutical formulation of Claim 1, wherein the formulation is dissolved in a pharmaceutically acceptable aqueous solution prior to administration to a mammal.

2. The pharmaceutical formulation of Claim 1, wherein the chelating agent is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA) salts, citrates, alginates, and combinations thereof.

2. The pharmaceutical formulation of claim 1, wherein the pH stabilizing salt is selected from the group consisting of citrate and sodium bicarbonate.

2. The pharmaceutical formulation of Claim 1, wherein the formulation further comprises a resin.

2. The pharmaceutical formulation of Claim 1, wherein the formulation further comprises zinc oxide.

2. The pharmaceutical formulation of Claim 1, wherein the formulation further comprises magnesium citrate.

2. A pharmaceutical formulation according to claim 1, wherein the formulation comprises the form of a chewable tablet.

2. The pharmaceutical formulation of Claim 1, wherein the formulation is provided in a nebulizer.

2. Pharmaceutical formulation according to claim 1, wherein lysozyme is present in an amount of 80% or less by weight relative to the total weight of the pharmaceutical formulation.

i. from about 2% to about 80% by weight lysozyme;
ii. from about 2% to about 40% by weight of a pharmaceutically acceptable chelating agent;
iii. A pharmaceutical formulation comprising from about 0.7% to about 20% by weight of a pharmaceutically acceptable pH stabilizing salt having a buffering capacity in the range of pH 3.0 to pH 7.0 , said pharmaceutical formulation comprising: A pharmaceutical preparation for treating or preventing disease.

12. Pharmaceutical formulation according to claim 11, wherein the infection is a respiratory infection.

12. The pharmaceutical formulation of Claim 11, wherein the composition is administered by a nebulizer.

12. The pharmaceutical formulation of Claim 11, wherein the composition is introduced into the bloodstream.

12. The pharmaceutical formulation of Claim 11, wherein the solution is introduced to the surgical site during a surgical procedure.

12. The pharmaceutical formulation of Claim 11, wherein administration treats or prevents sepsis.

12. Pharmaceutical formulation according to claim 11, wherein the bacterial infection is accompanied by a viral infection.

18. The pharmaceutical formulation according to claim 17, wherein the viruses causing viral infections are influenza, coronaviruses, adenoviruses, parvoviruses.

19. Pharmaceutical formulation according to claim 18, wherein the virus is SARS-CoV-2.

20. Pharmaceutical formulation according to claim 19, wherein the virus causes COVID-19.